)
Visual
test
GlaxoSmithKline Pharmaceuticals
GlaxoSmithKline Pharmaceuticals (500660) investor relations material
GlaxoSmithKline Pharmaceuticals Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 25/26 earnings summary6 Nov, 2025
Executive summary
Celebrated 101 years in India, focusing on general medicines, vaccines, and a renewed push into oncology with the launch of Jemperli and Zejula in Q2.
Specialty and vaccine segments delivered strong double-digit growth, while general medicines faced headwinds due to supply disruptions and a muted acute market.
Portfolio transformation, digital engagement, and leadership experience are driving competitiveness.
Unaudited consolidated Q2 and H1 FY2025-26 results were approved, with auditors confirming compliance and no material misstatements.
Board approved a ₹1.74 crore investment in a solar power project at Nashik to meet green energy needs and regulatory requirements.
Financial highlights
Q2 sales/revenue were INR 974 crore (₹97,994 lakhs), a decline of 2.6% year-over-year, mainly due to supply disruptions and GST changes.
EBITDA margin improved to 34.4%, up 250 basis points year-over-year, driven by cost savings and a better product mix.
EPS for Q2 was ₹15.06, a 3% increase year-over-year.
Net profit for Q2 was ₹25,749 lakhs, up from ₹20,501 lakhs in the previous quarter and ₹25,250 lakhs in Q2 last year.
Paediatric vaccines portfolio grew 13% year-over-year, led by key brands.
Outlook and guidance
Double-digit growth ambition remains intact, with supply chain issues resolved and a focus on innovative launches to drive recovery in H2.
No formal FY26 guidance provided, but priorities are restoring growth, maintaining sustainable EBITDA margins, and expanding gross margins.
Investment in renewable energy is expected to optimize energy costs and ensure compliance with captive power regulations.
CMO fire impact on full-year growth target?
How to sustain current high EBITDA margins?
Early patient uptake trends for oncology launch?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income.
Next GlaxoSmithKline Pharmaceuticals earnings date
Q3 25/2613 Feb, 2026
GlaxoSmithKline Pharmaceuticals
Next GlaxoSmithKline Pharmaceuticals earnings date
Q3 25/2613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
GlaxoSmithKline Pharmaceuticals Limited is an India-based pharmaceutical company engaged in the manufacturing, marketing, and distribution of prescription medicines and vaccines. The company operates across therapeutic areas such as respiratory, anti-infectives, dermatology, oncology, and vaccines. It is a subsidiary of GSK plc, a global biopharmaceutical company headquartered in the United Kingdom. GlaxoSmithKline Pharmaceuticals Limited serves healthcare professionals and institutions across India through a nationwide network. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage